Today's journal articles

Inhibition of presenilins attenuates proliferation and invasion in bladder cancer cells through multiple pathways.

The role of functional imaging in the era of targeted therapy of renal cell carcinoma.

Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report.

A comprehensive analysis of adiponectin QTLs using SNP association, SNP cis-effects on peripheral blood gene expression and gene expression correlation identified novel metabolic syndrome (MetS) genes with potential role in carcinogenesis and systemic inflammation.

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Evaluation of EGFR - targeted radioimmuno - gold - nanoparticles as a theranostic agent in a tumor animal model.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

A Study of RO5520985 in Patients With Locally Advanced or Metastatic Solid Tumors

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Previous Journal Entries

Xentry, a new class of cell-penetrating peptide uniquely equipped for delivery of drugs. Licensing Opportunity

Estrogen Receptor-α Variant, ER-α36, is Involved in Tamoxifen Resistance and Estrogen Hypersensitivity. Licensing Opportunity

Discovery of novel 4 - (2 - fluorophenoxy)quinoline derivatives bearing 4 - oxo - 1,4 - dihydrocinnoline - 3 - carboxamide moiety as c - Met kinase inhibitors.

A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.

Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model.

Anti - Neoplastic Activity of 1,3 - Diaza - 2 - Functionalized - Adamantan - 6 - One Compounds Against Melanoma Cells.

The effects of CD44 down-regulation on stem cell properties of head and neck cancer cell lines.

Mitochondria-specific nano-emulsified therapy for myocardial protection against Doxorubicin-induced cardiotoxicity.

The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.

Combinational effect of PPARγ agonist and RXR agonist on the growth of SGC7901 gastric carcinoma cells in vitro.

Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study.

Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms.

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study.

A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.

Altered cardiac muscle mTOR regulation during the progression of cancer cachexia in the ApcMin/+ mouse.

Cognitive Complaints After Breast Cancer Treatments: Examining the Relationship With Neuropsychological Test Performance.

MiR - 125b regulates side population in breast cancer and confers a chemoresistant phenotype.

Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and (18) F-FLT PET imaging.

MiR-150 Blocks MLL-AF9 Associated Leukemia By Repressing Multiple Oncogenes.

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Today's News Items

Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan

Training Courses & Meetings

No events listed

Previous News Items

Hologic Receives FDA Approval for a New Low-dose 3D Mammography (Breast Tomosynthesis) Solution for Breast Cancer Screening

CytRx Announces Initial Results from Pharmacokinetics Clinical Trial with Aldoxorubicin in Solid Tumors

Oncolytics Biotech® Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility

MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer

---

For faster discovery, automatically organize PubMed results into categories